Novo Nordisk A/S

ISIN US6701002056

 | 

WKN 866931

Market cap (in EUR)
217,567 m
Country
Denmark
Sector
Healthcare
Dividend yield
2.19%
 

Overview

Description

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.
Show more Show less
Healthcare Biopharmaceuticals System-Specific Biopharmaceuticals Denmark

Financials

Key metrics

Market capitalisation, EUR 217,567 m
EPS, EUR 3.11
P/B ratio 9.4
P/E ratio 16.4
Dividend yield 2.19%

Income statement (2024)

Revenue, EUR 38,934 m
Net income, EUR 13,539 m
Profit margin 34.78%
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH.

Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.